RXDX News and Press, Prometheus Biosciences Inc. From 04/17/23

2023-04-17 10:02:16 ET Gainers: Prometheus Biosciences ( RXDX ) +69% . CNS Pharmaceuticals ( CNSP ) +53% . Revelation Biosciences ( REVB ) +29% . Windtree Therapeutics ( WINT ) +26% . Kiromic BioPharma ( KRBP ) +22% . Loser...

2023-04-17 09:47:58 ET Prometheus Biosciences ( NASDAQ: RXDX ) had other bidders for the company besides Merck ( NYSE: MRK ). There was a competition to purchase Prometheus ( RXDX ), according to CNBC's David Faber, who cited people familiar. The $10.8 billion deal...

2023-04-17 07:08:24 ET Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify Merck ( MRK ) inks ~$11B all-cash deal to acquire Prometheus (RXDX). Fox News ( FOX ) defamation trial delayed amid reports of settlement...

2023-04-17 07:00:49 ET Summary Merck demonstrates its dominant position with its bold move to acquire Prometheus Biosciences for nearly $11 billion, offering a premium of over 75% above RXDX's Friday closing price. Merck faces a critical challenge in reducing its dependence on Key...

2023-04-17 06:39:02 ET Prometheus Biosciences ( NASDAQ: RXDX ) jumped ~70% in the pre-market Monday after Merck ( NYSE: MRK ) agreed to acquire the clinical-stage biotech for $10.8B in cash to expand the pharma giant's focus on immunology. However, Merck ( MRK ...

PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology Merck (NYSE: MR...

2023-03-15 13:51:48 ET The following slide deck was published by Prometheus Biosciences, Inc. in conjunction with this event. For further details see: Prometheus Biosciences I(RXDX) Investor Presentation - Slideshow

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases...

Summary The stock of Prometheus Biosciences has tripled since positive mid-stage trial results for its primary candidate for treating UC and CD came out in early December. Since then the company has done a large capital raise and there have been some significant insider sales so far in ...

Prometheus Biosciences press release ( NASDAQ: RXDX ): Q4 GAAP EPS of -$0.90 beats by $0.01 . Revenue of $0.65M (-37.5% Y/Y) beats by $0.18M . For further details see: Prometheus Biosciences GAAP EPS of -$0.90 beats by $0.01, revenue of $0.65M beats by $0.18M